Diabetes
From the Journals
The best statins to lower non-HDL cholesterol in diabetes?
Rosuvastatin, simvastatin, and atorvastatin were most effective in reducing levels of non-HDL cholesterol in people with diabetes in a network...
Conference Coverage
Combo of SGLT2 inhibitor + GLP-1 RA boosts diabetes survival
Survival of patients with type 2 diabetes and CVD rose by 80% when they received both an SGLT2 inhibitor and GLP-1 RA, compared with either class...
Guidelines
AHA statement addresses CVD risk in NAFLD
The American Heart Association has issued a new scientific statement addressing cardiovascular risk in nonalcoholic fatty liver disease.
Conference Coverage
Better survival in older cancer patients who take metformin
“It is important to explore optimal dosages that significantly improve cancer outcomes to boost anticancer effect.”
Conference Coverage
High comorbidity rate seen before osteoarthritis diagnosis
More than 40 medical conditions were positively associated with having a new diagnosis of osteoarthritis in a large, nested case-control study.
Conference Coverage
Empagliflozin rapidly improves acute heart failure symptoms in hospitalized patients
Empagliflozin showed symptomatic benefits in patients hospitalized for acute heart failure after 2 weeks in a secondary analysis from the EMPULSE...
From the Journals
‘Forever chemicals’ exposures may compound diabetes risk
The increased risk of diabetes observed among women exposed to a combination of ‘forever chemicals’ is similar to that associated with overweight...
From the Journals
Type 1 diabetes not just a childhood-onset disease
Despite popular belief that type 1 diabetes is a disease that starts in childhood, its onset in adults is substantial, researchers report.
Conference Coverage
Type 2 diabetes remission possible for those with lower BMI
Having a normal BMI is no barrier to experiencing type 2 diabetes remission with a structured weight-loss program, show U.K. results.
Conference Coverage
New HF guidelines feature ‘quad’ therapy, tweaked terminology
They include new generalist-friendly labels for the traditional but obscurely named four stages of HF that, it is hoped, will have wider reach and...
Conference Coverage
SCORED: Sotagliflozin shows robust MACE benefit
Trial results in patients with diabetes, CKD, and high CVD risk showed robust benefits across MACE outcomes, distinguishing sotagliflozin from the...